Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan.
Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Bone Marrow Transplant. 2024 Aug;59(8):1107-1117. doi: 10.1038/s41409-024-02297-0. Epub 2024 May 7.
Poor prognostic factors, such as transfusion dependency and chromosomal risk, need to be considered in the indication of allogeneic hematopoietic cell transplantation (allo-HCT) for patients harboring myelodysplastic syndromes with less than 5% marrow blasts (MDS-Lo). We analyzed the post-transplant outcomes of 1229 MDS-Lo patients who received myeloablative (MAC)(n = 651), reduced-intensity (RIC)(n = 397), and non-myeloablative conditioning (NMAC) regimens (n = 181). The multivariate analysis revealed that the RIC group had better chronic graft-versus-host disease (GVHD)- and relapse-free survival (CRFS) (P = 0.021), and GVHD- and relapse-free survival (GRFS) than the MAC group (P = 0.001), while no significant differences were observed between the NMAC and MAC groups. In the subgroup analysis, the MAC group has better overall survival (P = 0.008) than the RIC group among patients with an HCT-comorbidity index (HCT-CI) score of 0, while the RIC group had better overall survival (P = 0.029) than the MAC group among those with an HCT-CI score ≥3. According to the type of conditioning regimen, total body irradiation 12 Gy-based MAC regimen showed better OS and CRFS than the other MAC regimen, and comparable outcomes to the RIC regimen. In conclusion, the RIC and NMAC regimens are promising options for MDS-Lo patients in addition to the MAC regimen.
对于骨髓增生异常综合征(MDS)患者,如果骨髓原始细胞数<5%(MDS-Lo),并且存在输血依赖和染色体风险等不良预后因素,需要考虑行异基因造血细胞移植(allo-HCT)。我们分析了 1229 例接受清髓性(MAC)(n=651)、减低强度(RIC)(n=397)和非清髓性预处理(NMAC)(n=181)allo-HCT 的 MDS-Lo 患者的移植后结局。多变量分析显示,RIC 组慢性移植物抗宿主病(GVHD)-无复发存活率(CRFS)(P=0.021)和 GVHD-无复发存活率(GRFS)(P=0.001)优于 MAC 组,而 NMAC 组与 MAC 组之间无显著差异。在亚组分析中,在 HCT 合并症指数(HCT-CI)评分 0 的患者中,MAC 组的总生存(OS)优于 RIC 组(P=0.008),而在 HCT-CI 评分≥3 的患者中,RIC 组的 OS 优于 MAC 组(P=0.029)。根据预处理方案的类型,基于 12Gy 全身照射的 MAC 方案在 OS 和 CRFS 方面优于其他 MAC 方案,与 RIC 方案的结果相当。总之,除了 MAC 方案外,RIC 和 NMAC 方案也是 MDS-Lo 患者的有前途的选择。